In this second patient case video from BREAST CANCER CONNECT, Prof. Maria Vittoria Dieci delves into the continuation of a patient case with ER+/HER2- metastatic breast cancer initially presented in our first video of this series.

Throughout this journey, we'll explore what to expect after prescribing elacestrant and take a closer look at patient-reported outcomes in the EMERALD trial.

Catch up on the first video to hear Prof Francois-Clement Bidard discuss how to optimise treatment selection and make appropriate sequencing decisions for patients with ER+/HER2- metastatic breast cancer.

Clinical Takeaways

  • PROs results demonstrating no difference between treatment arms in the EMERALD trial, support elacestrant as a clinically meaningful option in this setting

  • Elacestrant has a manageable safety profile

  • If a patient progresses on elacestrant, the choice of subsequent therapy line should be based on multiple factors, including sensitivity to prior treatments, disease burden, and tumour biology. In this context, ADCs represent a new option

  • Recognise the efficacy and safety profiles of SERDs for patients with advanced or metastatic BC, and understand their place in the treatment landscape for patients with BC
  • Implement optimization of treatment selection, and make the appropriate sequencing decisions
  • Be able to identify and manage adverse events

Maria Vittoria Dieci, MD, is Associate Professor at the University of Padova, vice-director of the Specialization School in Medical Oncology at the same University and attending physician at the Division of Oncology 2 of the Istituto Oncologico Veneto in Padova. She specialised in Oncology in March 2012 at the University of Modena. From May 2012 to November 2013 she completed a 18-month-research experience at the Translational Research Unit (INSERM U981) of the Gustave Roussy Institute (Villejuif, France), and obtained the “Diplome Universitaire Européen en Recherche Translationnelle et Clinique en Cancérologie”. Since November 2013 she has been conducting research and clinical activity in the field of breast cancer at the University of Padova / Istituto Oncologico Veneto IRCCS.

She is panelist of the Breast Cancer Guidelines by the Italian Association of Medical Oncology. Prof Dieci’s research production from 2008 up till now consists of more than 140 papers in peer-reviewed journals.

Prof. Maria Vittoria Dieci has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Eli Lilly, Pfizer, Novartis, Roche, Exact Science, Daiichi Sankyo, Gilead, Seagen.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Menarini Stemline Oncology.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast

Episode

4

of 4

episode
Oncology 
HCC podcast series part 4: Intermediate HCC – the evolving role of IO

Integrating multimodal approaches with multidisciplinary care

Experts
Dr Edward Kim, Dr Nina Sanford, Dr Mark Yarchoan, Oncology Brothers (Moderators)
Endorsed by
Blue Faery plus Global Liver Institute DiCE
ELPA
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
video Video
Oncology 
The evolving role of liquid biopsy in HR+/HER2- metastatic breast cancer

Exploring the impact of liquid biopsy in advanced breast cancer

Experts
Prof. Frédérique Penault-Llorca, Dr Aditya Bardia
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
animated-video Animated Video
Oncology Obstetrics and Gynecology 
Current treatment options in advanced/recurrent endometrial cancer

Exploring the impact of molecular subtypes 

Experts
Prof. Christian Marth
  • download Downloadable
    Resources
  • clock 7 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme.
podcast Podcast

Episode

3

of 4

episode
Oncology 
HCC podcast series part 3: Intermediate HCC – treatment options and strategies

Expert insights on systemic, loco-regional, and multimodal therapies

Experts
Dr Maria Reig, Dr Emil I Cohen, Oncology Brothers (Moderators)
Endorsed by
DiCE Blue Faery plus Global Liver Institute
ELPA
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Recent advances in precision oncology and future implications

Two emerging and two established targets

Experts
Prof. David Hong
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Announcing the publication of survey results 

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.